YOLFTbeta
Omeros Corporation

Omeros Corporation

OMER · NASDAQ · Healthcare / Biotechnology

17.49USD-0.50 (-2.78%)

Price History

Full chart

Market Stats

Previous Close17.99
Open17.93
Day Range17.08 – 18.04
52-Week Range4.06 – 21.24
Volume737.20K
Market Cap1.41B
P/E (TTM)12.14
Forward P/E87.72
EPS1.60
Dividend Yield0.00%
Beta2.60
50-Day Avg16.21
200-Day Avg12.82

About

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Gregory A. Demopulos M.D.
  • Employees175
  • HeadquartersThe Omeros Building, Seattle, WA, United States, 98119, USA
  • Websitehttps://www.omeros.com

Leadership

  • Dr. Gregory A. Demopulos M.D.Co-Founder, Chairman, CEO & President · b. 1959
  • Mr. David J. BorgesVP of Finance, Chief Accounting Officer & Treasurer · b. 1965
  • Mr. Peter B. Cancelmo J.D.VP, General Counsel & Corporate Secretary · b. 1979
  • Dr. Pamela Pierce Palmer M.D., Ph.D.Co-Founder · b. 1963
  • Dr. George A. Gaitanaris M.D., Ph.D.Chief Scientific Officer & VP of Science · b. 1957
  • Mr. Peter W. WilliamsVice President of Human Resources · b. 1968
  • Dr. Catherine A. Melfi Ph.D.Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems · b. 1959
  • Mr. David W. GhesquiereVP & Chief Business Development Officer · b. 1967
  • William E. WoodmanVP & Chief Commercial Officer

Financials

Income Statement

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-200.00K1.92M1.17M1.44M2.10M4.52M6.02M1.60M539.00K13.51M41.62M64.83M29.87M111.81M73.81M90.52M0000
Growth (%)--+861.50%-39.16%+23.42%+45.78%+114.92%+33.11%-73.43%-66.31%+2406.31%+208.07%+55.77%-53.93%+274.33%-33.98%+22.64%-100.00%---
Cost of Revenue--25.95M25.26M21.75M31.24M31.50M18.46K18.33M26.73M1.04M1.41M1.08M512.00K2.65M1.62M1.39M952.00K69.78M950.00K-
Gross Profit-200.00K1.92M1.17M1.44M2.10M4.52M6.00M-16.73M-26.19M12.47M40.20M63.75M29.36M109.15M-1.62M-1.39M-952.00K-69.78M-950.00K-
Gross Margin-100.00%100.00%100.00%100.00%100.00%100.00%99.69%-1045.38%-4858.81%92.29%96.61%98.34%98.29%97.63%-2.19%-1.53%----
Operating Expense-24.15M26.32M25.70M22.20M32.21M31.93M42.89M33.79M43.82M83.71M94.48M107.64M141.58M172.53M155.30M172.23M162.44M94.75M168.31M-
Operating Income-7.71M-23.95M-24.40M-24.52M-20.76M-30.11M-27.41M-36.88M-50.52M-70.01M-71.24M-54.28M-43.90M-112.22M-63.38M-156.92M-173.62M-163.39M-164.53M-169.26M-122.80M
Operating Margin--11976.50%-1268.69%-2096.15%-1437.53%-1430.21%-605.88%-612.50%-3157.25%-12988.50%-527.34%-130.42%-67.71%-375.73%-56.69%-212.59%-191.80%----
EBITDA-7.37M-22.45M-22.57M-24.09M-18.44M-27.24M-26.23M-36.40M-37.13M-69.88M-71.31M-58.63M-41.90M-122.47M-60.04M-168.02M-170.49M-158.38M-143.16M-157.00M-1.83M
EBITDA Margin--11227.00%-1173.43%-2059.06%-1276.73%-1294.25%-579.73%-604.37%-2320.50%-12964.19%-527.90%-140.87%-64.63%-410.04%-53.70%-227.63%-188.34%----
Net Income-7.37M-22.78M-23.09M-23.83M-21.09M-29.25M-28.55M-38.44M-39.80M-73.67M-75.10M-66.75M-53.48M-126.76M-84.49M-138.06M-111.41M47.42M-117.81M-156.81M-3.35M
Net Income Margin--11388.50%-1200.78%-2036.50%-1460.46%-1389.60%-630.99%-638.39%-2487.25%-13668.46%-555.90%-160.38%-82.50%-424.39%-75.57%-187.04%-123.08%----
R&D5.80M20.53M15.92M17.85M16.93M23.46M23.72M31.92M36.30M47.95M48.38M50.70M55.60M89.86M109.70M107.61M118.78M112.72M114.87M119.52M81.30M
R&D as % of Total Revenue-10264.00%827.98%1525.64%1172.37%1114.73%524.27%530.09%2268.56%8895.36%358.12%121.82%85.77%300.86%98.11%145.79%131.21%----
Interest Expense-91.00K151.00K335.00K2.20M1.53M1.88M1.73M2.37M3.47M3.57M7.82M11.03M16.25M22.66M26.75M19.67M22.70M30.84M24.68M960.00K
Interest Expense % of Total Revenue-45.50%7.85%28.63%152.49%72.92%41.64%28.71%147.88%643.78%26.45%18.79%17.01%54.41%20.26%36.24%21.73%----

Balance Sheet

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--27.16M21.68M62.06M45.70M26.98M26.57M16.54M11.09M48.99M67.28M116.33M95.94M136.97M181.04M419.27M590.97M378.27M277.08M325.63M
Total Liabilities--97.10M112.85M18.92M25.23M32.54M241.15M34.92M53.74M75.23M104.72M119.14M-4.22M245.99M301.79M395.49M505.29M403.25M459.69M446.86M
Total Equity---69.94M-91.17M43.15M20.47M-5.55M-214.58M-18.38M-42.65M-26.23M-37.45M-2.81M650.13M-109.02M-120.75M23.78M85.68M-24.98M-182.61M-121.23M
Cash--5.92M12.73M820.00K3.28M4.00M1.52M1.38M354.00K1.36M2.22M3.39M5.86M3.08M10.50M100.81M11.01M7.11M3.40M9.66M
Total Debt--1.01M16.67M12.76M9.76M19.45M20.10M20.50M32.71M50.05M80.03M84.61M151.45M161.72M240.07M347.84M342.02M361.58M207.02M239.14M
Net Debt---4.92M3.95M11.94M6.48M15.44M18.58M19.11M32.35M48.68M77.81M81.21M145.59M32.74M22.05M247.03M331.01M354.48M203.62M229.48M

Cash Flow

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.17M-14.31M-19.67M-19.03M-14.50M-25.67M-34.55M-29.70M-58.04M-65.21M-51.50M-36.23M-103.74M-60.07M-100.09M-109.72M-86.48M74.73M-148.80M-116.09M
Investing Cash Flow-579.00K-6.09M10.57M-52.40M19.92M16.91M-907.00K7.91M6.16M-20.61M-16.34M-37.60M25.15M-3.40M-67.03M193.71M-127.56M27.45M82.22M164.52M
Financing Cash Flow33.90M2.93M15.91M59.52M-2.96M9.49M32.97M21.65M50.86M86.83M68.70M75.00M81.05M60.70M174.53M6.32M124.25M-106.08M62.88M-42.17M
Capital Expenditure166.00K534.00K164.00K279.00K8.44M1.24M642.00K204.00K28.00K240.00K126.00K350.00K567.00K334.00K283.00K277.00K113.00K426.00K165.00K65.00K
Free Cash Flow-10.34M-14.85M-19.84M-19.31M-22.94M-26.91M-35.19M-29.90M-58.07M-65.45M-51.63M-36.58M-104.30M-60.41M-100.37M-110.00M-86.60M74.30M-148.97M-116.16M
Dividends Paid-----3.15M000000--------
FCF to OCF101.63%103.73%100.83%101.47%158.19%104.83%101.86%100.69%100.05%100.37%100.24%100.97%100.55%100.56%100.28%100.25%100.13%99.43%100.11%100.06%
Dividend Paid to FCF------11.69%0.00%0.00%0.00%0.00%0.00%0.00%--------

Earnings

Report DateNov 19, 2009Mar 31, 2010May 12, 2010Aug 10, 2010Nov 4, 2010Mar 15, 2011May 10, 2011Aug 9, 2011Nov 8, 2011Mar 15, 2012May 10, 2012Aug 7, 2012Nov 9, 2012Mar 18, 2013May 9, 2013Aug 9, 2013Nov 7, 2013Mar 13, 2014May 12, 2014Aug 11, 2014Nov 10, 2014Mar 16, 2015May 11, 2015Aug 10, 2015Nov 9, 2015Mar 7, 2016May 10, 2016Aug 9, 2016Nov 9, 2016Mar 16, 2017May 10, 2017Aug 8, 2017Nov 9, 2017Mar 1, 2018May 10, 2018Aug 9, 2018Nov 8, 2018Mar 1, 2019May 9, 2019Aug 8, 2019Nov 12, 2019Mar 2, 2020May 11, 2020Aug 10, 2020Nov 9, 2020Mar 1, 2021May 10, 2021Aug 9, 2021Nov 9, 2021Mar 1, 2022May 10, 2022Aug 9, 2022Nov 9, 2022Mar 13, 2023May 9, 2023Aug 9, 2023Nov 9, 2023Mar 26, 2024May 15, 2024Aug 7, 2024Nov 13, 2024Mar 31, 2025May 15, 2025Aug 14, 2025Nov 13, 2025Mar 3, 2026May 13, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate-0.37-0.27-0.29-0.33-0.39-0.42-0.39-0.36-0.39-0.35-0.38-0.36-0.34-0.34-0.39-0.38-0.44-0.38-0.45-0.57-0.57-0.62-0.62-0.56-0.49-0.59-0.43-0.49-0.36-0.56-0.35-0.37-0.34-0.17-0.59-0.62-0.71-0.81-0.47-0.44-0.41-0.50-0.34-0.59-0.49-0.69-0.51-0.55-0.47-0.36-0.69-0.66-0.58-0.57-0.57-0.53-0.66-0.55-0.63-1.01-0.77-0.71-0.58-0.55-0.48-0.52-0.39-0.27-0.05
EPS Actual-0.33-0.28-0.31-0.34-0.35-0.32-0.30-0.24-0.29-0.46-0.40-0.38-0.36-0.45-0.40-0.48-0.46-0.47-0.54-0.53-0.54-0.61-0.51-0.44-0.53-0.49-0.54-0.32-0.34-0.45-0.34-0.33-0.16-0.34-0.62-0.70-0.81-0.21-0.50-0.29-0.33-0.58-0.53-0.61-0.34-0.60-0.57-0.46-0.36-0.37-0.53-0.66-0.872.05-0.63-0.70-0.82-0.15-0.75-1.12-0.64-0.55-0.65-0.53-0.32-0.550.570.02-
Surprise10.81%-3.70%-6.90%-3.03%10.26%23.81%23.08%33.33%25.64%-31.43%-5.26%-5.56%-5.88%-32.35%-2.56%-26.32%-4.55%-23.68%-20.00%7.02%5.26%1.61%17.74%21.43%-8.16%16.95%-25.58%34.69%5.56%19.64%2.86%10.81%52.94%-100.00%-5.08%-12.90%-14.08%74.07%-6.38%34.09%19.51%-16.00%-55.88%-3.39%30.61%13.04%-11.76%16.36%23.40%-2.78%23.19%0.00%-50.00%459.65%-10.53%-32.08%-24.24%72.73%-19.05%-10.89%16.88%22.54%-12.07%3.64%33.33%-5.04%246.15%107.41%-
Timing--After-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.41B
Enterprise Value1.53B
Trailing P/E12.14
Forward P/E87.72
PEG Ratio0.81
Price / Sales36.61
Price / Book8.44
EPS1.60
Book Value-0.712
Revenue (TTM)38.42M
Gross Profit (TTM)14.73M
EBITDA-71.91M
Profit Margin324.88%
Operating Margin0.26%
Return on Equity-576.33%
Return on Assets-18.68%
Shares Outstanding72.39M
Shares Float69.29M
Beta2.60
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 27.50
  • Strong Buy
    2
  • Hold
    2

Ownership Breakdown

Institutions
50.94%
Insiders
4.08%
Retail / Other
44.98%

Top Institutional Holders

  • BlackRock Inc
    5.31M7.33%
  • Ingalls & Snyder LLC
    3.56M4.92%
  • Vanguard Capital Management, LLC
    2.98M4.12%
  • UBS Group AG
    2.34M3.23%
  • State Street Corp
    1.92M2.65%
  • Stifel Financial Corp
    1.83M2.53%
  • Geode Capital Management, LLC
    1.75M2.42%
  • Vanguard Portfolio Management, LLC
    718.67K0.99%
  • Rock Springs Capital Management LP
    718.50K0.99%
  • CI Private Wealth LLC
    659.73K0.91%
  • Charles Schwab Investment Management Inc
    582.51K0.80%
  • BMO Capital Markets Corp.
    568.43K0.79%
  • Bank of Montreal
    568.42K0.79%
  • Northern Trust Corp
    563.87K0.78%
  • Vanguard Fiduciary Trust Co
    492.35K0.68%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.17M3.00%
  • iShares Russell 2000 ETF
    1.85M2.55%
  • Invesco Biotechnology & Genome ETF
    929.59K1.28%
  • State Street® SPDR® S&P® PhrmctlsETF
    837.79K1.16%
  • Fidelity Small Cap Index
    781.12K1.08%